Loading
AVC-201 is an experimental allogeneic CRISPR-engineered switchable CAR-T cell therapy from AvenCell Therapeutics, in phase 1 trials for CD123-positive relapsed/refractory or MRD-positive acute myeloid leukaemia.
AVC-201 (Allo-RevCAR01-T-CD123, Allo-RevCAR01-T with R-TM123) is an allogeneic CRISPR-engineered switchable CAR-T cell therapy (RevCAR, with separately dosed targeting module) from AvenCell Therapeutics, with Intellia Therapeutics as partner. Donor T cells, gene-edited with CRISPR to avoid graft-versus-host disease and rejection, carrying a switchable receptor activated only by a separately infused CD123 targeting module, so activity can be switched off and on. Its furthest stage is phase 1, for CD123-positive relapsed/refractory or MRD-positive acute myeloid leukaemia. ClinicalTrials.gov registers it in one study linked below. Phase 1a portion of RevSTAR-123 completed; results presented as an EHA 2026 late-breaking plenary oral (company release 2 June 2026). Registry status recruiting. Whether it works in people has not been established unless a trial below reports it.
Donor T cells, gene-edited with CRISPR to avoid graft-versus-host disease and rejection, carrying a switchable receptor activated only by a separately infused CD123 targeting module, so activity can be switched off and on. Connects to CD123.
1.AVC-201 slips into a pocket on CD123.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AVC-201" OR ABSTRACT:"AVC-201" OR TITLE:"Allo-RevCAR01-T-CD123" OR ABSTRACT:"Allo-RevCAR01-T-CD123" OR TITLE:"Allo-RevCAR01-T with R-TM123" OR ABSTRACT:"Allo-RevCAR01-T with R-TM123") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AVC-201, not a curated reading list.
Shares CD123, AvenCell Therapeutics and the tag pipeline.
Shares CD123, Acute myeloid leukaemia and the tag pipeline.
Shares AvenCell Therapeutics and the tag pipeline.
Shares AvenCell Therapeutics and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/